Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

By TOM MURPHY
AP Health Writer

Biogen will stop selling its Alzheimer’s treatment Aduhelm. The drug was once seen as a potential blockbuster but it stumbled after its launch a few years ago. The drugmaker also said Wednesday that it will end a study of the drug needed for full approval from the Food and Drug Administration. Patients taking doses of Aduhelm available through the commercial market can continue until November. A company representative said there are about 2,500 people worldwide taking Aduhelm. Biogen said it will turn its  focus to other treatments for the fatal, mind-robbing disease.